Tag: Bayer

Bayer shareholders endured a rough session on Friday as the stock shed nearly 3% to close at €38.87, despite management's ...

Bayer enters one of its most consequential weeks in years, with a Supreme Court hearing on glyphosate liability looming just ...

Bayer shareholders have handed management a powerful financial weapon. At the company’s annual general meeting, they approved a blanket authorization ...

The contrast at Bayer has rarely been starker. At its Leverkusen headquarters, the company is celebrating a prestigious industry award ...

The coming days represent a defining moment for Bayer AG as two pivotal events converge, threatening to either cap a ...

The coming weeks will be critical for Bayer as two distinct but significant timelines—one legal, one financial—reach pivotal moments. While ...

April marks a critical juncture for Bayer, the Leverkusen-based life sciences conglomerate, as two major events converge. While the company's ...

Bayer faces a period of significant transition as declining revenues from its former blockbuster drugs compel urgent strategic action. The ...

Bayer's ongoing corporate restructuring is encountering turbulence from two significant external forces. As geopolitical tensions flare and energy costs climb, ...

Bayer AG finds itself at a confluence of strategic developments, with a new flagship location, steady share price action, and ...